REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries
REGiMMUNE Limited (REGiMMUNE), a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, and San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd. (4755.TW) have entered a licensing agreement to develop and commercialize RGI-2001 for the prophylaxis of acute Graft-versus-host disease (aGvHD) in major Asian countries.
RGI-2001, with the novel mechanism to improve existing treatments, is a potentially first-in-class small molecule drug candidate targeted for preventing aGvHD, a life-threatening complication resulting from allogeneic hematopoietic stem cell transplantation (HSCT). GvHD is a systemic disorder that occurs when the graft's immune cells recognize the host as foreign and attack the recipient’s body cells or organs, and leads to skin rash, liver problems, abdominal pain or cramps, diarrhea, and increased risk for infections. Patients undergoing allogeneic HSCT have a high-risk of developing aGVHD associated with significant morbidity and mortality. Despite the use of prophylactic immunosuppressive therapy, clinically significant aGvHD develops in 20%-40% of HLA-matched related and unrelated allogeneic HSCT and severe cases contribute to non-relapse mortality.
Under the terms of agreement, REGiMMUNE and SFB will collaborate closely to accelerate the development of RGI-2001 in major Asian countries and will conduct clinical trials to study the efficacy of the drug in aGvHD. Together, both parties intend to submit an Investigational New Drug Application to the Taiwan Food and Drug Administration to initiate clinical trials in Taiwan for the prophylaxis of aGvHD before the end of 2023. SFB will pay to REGiMMUNE development milestones and royalties on net profit upon successful commercialization of RGI-2001. SFB also retains the first rights of negotiation to develop and commercialize RGI-2001 for new indications in the authorized territories.
RGI-2001 of REGiMMUNE, awarded Orphan Drug Designation by the US FDA in GvHD in 2012, has completed the phase II clinical trial targeting at the prophylaxis of aGvHD in the US. The efficacy and safety results were positive. Furthermore, RGI-2001 was selected for oral presentation at the American Society of Hematology (ASH) annual meeting in December 2022 and planned to submit phase III IND to US FDA in Q4 of 2023.
Kenzo Kosuda, Chief Executive Officer and President, REGiMMUNE Limited, said: “This agreement underscores our focus and commitment to improve the incumbent therapies of aGvHD prevention and treatment. The fast-growing patients with GvHD in Asia create a high unmet need for more effective treatments.”
“We are pleased to collaborate with SFB and San Fu Chemical Group which has a long history in Taiwan. The Group’s abundant biomedical resources, expertise and innovative strategy make San Fu a strong commercial partner for REGiMMUNE in Asia. Together, we look forward to expediting the development of RGI-2001 in this important market.”
Simon H.H. Wu, SFB & San Fu Chemical Group Chairman, emphasized:“We are excited to add RGI-2001 to our growing portfolio of innovative therapeutic agents. This enhances our autoimmune pipeline and aligns with our long-term research and development strategy. RGI-2001 has demonstrated promising results in phase II studies in the US and we look forward to working together with REGiMMUNE to deliver treatments that will benefit the lives of patients.”
RGI-2001 is a liposomal formulation of an alpha-galactosylceramide (alpha-GalCer) analog. Alpha-GalCer is a ligand for CD1d expressed on antigen presenting cells and invariant natural killer T cells (iNKT). Liposomal alpha-GalCer promotes tolerogenic immune cascades, resulting in the activation and expansion of regulatory T cells (Tregs).
RGI-2001 is REGiMMUNE’s lead drug candidate currently in Phase 3 planning for the prophylaxis of acute graft-versus-host disease (aGVHD).
About REGiMMUNE Limited
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). REGiMMUNE is creating a pipeline of novel product candidates that either enhance Treg activities for immune diseases or suppress Treg activities for cancer.
About San Fu Biotech
San Fu Biotech, a wholly-owned subsidiary of San Fu Chemical, develops first-in-class new drugs to address unmet medical needs, such as cancer tumors, autoimmune disease and ophthalmology, for benefiting patients around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230401005026/en/
Chief Financial Officer
Tel: +886 2 2555 3377 #511
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SAP S/4HANA is Driving Nordics in a Digital Direction8.6.2023 10:00:00 CEST | Press release
Enterprise demand for SAP transformation services in the Nordics has grown exponentially over the past 12 months, as companies seek industry-specific solutions and accelerate their cloud transformations,according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2023 ISG Provider Lens™ SAP Ecosystem report for the Nordics finds the planned phase-out of support for SAP’s ERP Central Component (ECC) in 2027 has led to increased adoption of SAP S/4HANA. In the Nordic region, RISE with SAP, a unified ERP-as-a-service offering, has played a major role in enterprises embracing SAP in the cloud. “There is a rising call in the Nordics for increased SAP cloud services,” said Anthony Drake, ISG director, North Europe. “Providers have responded by extending their partnerships both with SAP and with hyperscalers.” Expansion of the SAP market has led to a growing focus on certification and training
Stallergenes Greer Foundation Science Awards for Allergy 2023: Call for Applications8.6.2023 10:00:00 CEST | Press release
The Stallergenes Greer Foundation aims to create healthier futures for all. The Foundation, under the aegis of the Fondation de France, is philanthropically dedicated to three focus areas: Advancing scientific research to bolster innovation and precision medicine. Supporting academic initiatives to further develop future generations of allergy healthcare professionals. Engaging in climate action and environmental protection to progress the prevention and treatment of allergies. Submissions are open for the Stallergenes Greer Foundation Science Awards for Allergy 2023. A total of €150,000 will be awarded for outstanding work led either by a young scientist or a mid-career scientist to advance precision medicine in the field of allergy, or outstanding work in the environmental field to advance the prevention and treatment of allergies. The Stallergenes Greer Foundation Science Awards for Allergy are presented in two areas: - Innovation Awards: two awards will be presented either to encou
Europcar Selects BringOz to Digitize and Streamline Vehicle Movements In Switzerland8.6.2023 09:00:00 CEST | Press release
As the largest vehicle rental company in Switzerland, Europcar’s fleet encompasses 5,500 vehicles including small cars, family vans, luxury sedans, commercial vehicles, convertibles and more. With over 90 locations, Europcar provides convenient pick-up and drop-off stations throughout Switzerland. Europcar Switzerland has chosen to work with BringOz’ logistics platform as part of its overall efforts to digitize internal processes and achieve the following goals: Automate and Optimize Vehicle Movements: BringOz digitizes vehicle movements and matches vehicle supply with consistently changing demand. The Europcar team will plan, execute and monitor vehicle transfer across all locations. Streamline Processes and Maximize Resources: The Europcar team will streamline processes, save time and reduce costs by increasing the efficiency of vehicle transfers with consolidation and better use of resources. Improve Team Productivity and Drive Revenue Growth: The Europcar team will focus more time
SES Space & Defense Delivers Satellite Connectivity to AWS Modular Data Center for the U.S. Department of Defense8.6.2023 08:50:00 CEST | Press release
SES Space & Defense, a wholly-owned subsidiary of SES, today announced the availability of flexible, secure, and reliable satellite-powered network connectivity for AWS Modular Data Center. AWS Modular Data Center makes it easy for the U.S. Department of Defense (DoD) to deploy modular data centers managed by Amazon Web Services (AWS) in infrastructure-limited locations. In February 2023, AWS announced the availability of AWS Modular Data Center to the DoD under the Joint Warfighting Cloud Capability (JWCC) contract. Leveraging SES’s multi-orbit, multi-band global fleet of satellites with AWS Modular Data Center, defense customers can access low-latency, cloud-based applications and services securely in Denied, Disrupted, Intermittent, and Limited (DDIL) environments through a dedicated network connection to AWS Regions. The U.S. DoD customers will also be able to leverage SES’s second-generation medium earth orbit (MEO) constellation, O3b mPOWER, designed with an open architecture app
Climate Impact X Launches CIX Exchange to Level up Carbon Market Transparency, Certainty and Liquidity8.6.2023 02:00:00 CEST | Press release
Climate Impact X (CIX), a global marketplace, auctions house and exchange for trusted carbon credits, has successfully launched its spot trading platform, CIX Exchange, completing the company’s core solutions suite with three operational venues. Powered by Nasdaq's trading technology, CIX Exchange offers carbon market professionals a customised experience built on international best practices for platform stability, performance and governance. Users can efficiently discover market-driven prices, compare individual projects and trade standard contracts. To address industry calls for greater transparency and price certainty, CIX has introduced the first daily on-exchange liquidity window in the voluntary carbon market with firm bids and offers. This dedicated 30-minute pricing session pools all-day liquidity from Asia, Europe and Middle East to help sharpen benchmark prices and improve order depth for spot nature-based credits. By close of trading on 7 June 2023, bids and offers had conv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom